In the last trading session, 3.42 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.48. With the company’s per share price at $7.97 changed hands at $0.66 or 9.03% during last session, the market valuation stood at $367.48M. URGN’s last price was a discount, traded about -159.72% off its 52-week high of $20.70. The share price had its 52-week low at $6.46, which suggests the last value was 18.95% up since then.
Analysts gave the UroGen Pharma Ltd (URGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended URGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. UroGen Pharma Ltd’s EPS for the current quarter is expected to be -0.79.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Instantly URGN was in green as seen at the end of in last trading. With action -28.46%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -25.16%, with the 5-day performance at -28.46% in the red. However, in the 30-day time frame, UroGen Pharma Ltd (NASDAQ:URGN) is -17.58% down.
The consensus price target for the stock as assigned by Wall Street analysts is 40, meaning bulls need an upside of 80.08% from its current market value. According to analyst projections, URGN’s forecast low is 22 with 60 as the target high. To hit the forecast high, the stock’s price needs a -652.82% plunge from its current level, while the stock would need to soar -176.04% for it to hit the projected low.
UroGen Pharma Ltd (URGN) estimates and forecasts
Year-over-year growth is forecast to reach 32.37% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 22.72M. 8 analysts are of the opinion that UroGen Pharma Ltd’s revenue for the current quarter will be 31.34M. The company’s revenue for the corresponding quarters a year ago was 21.85M and 25.2M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 4.00%. The estimates for the next quarter sales put growth at 24.33%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.39%. The 2025 estimates are for UroGen Pharma Ltd earnings to increase by 1.22%.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.9621% or 3.3 million shares worth $55.37 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund. With 998.29 shares estimated at $7.96 million under it, the former controlled 2.17% of total outstanding shares. On the other hand, Fidelity Salem Street Trust-Fidelity Small Cap Index Fund held about 0.83% of the shares, roughly 382.87 shares worth around $3.05 million.
